Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study | Zendy

Archana Thakur | Zendy; John Scholler | Zendy; Dana L. Schalk | Zendy; Carl H. June | Zendy; Lawrence G. Lum | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study

Author(s) -

Archana Thakur,

John Scholler,

Dana L. Schalk,

Carl H. June,

Lawrence G. Lum

Publication year - 2020

Publication title -

journal of cancer research and clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.338

H-Index - 94

eISSN - 1432-1335

pISSN - 0171-5216

DOI - 10.1007/s00432-020-03260-4

Subject(s) - cd19 , cytotoxicity , chimeric antigen receptor , cancer research , antigen , t cell , cell culture , antibody , cell , antibody dependent cell mediated cytotoxicity , medicine , immunology , immune system , chemistry , biology , in vitro , monoclonal antibody , genetics , biochemistry

Although adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells has shown durable clinical efficacy in patients with CD19 + B cell malignancies, the application of this approach to solid tumors is challenging. The goal of this proof-of-concept study was to investigate whether loading of CD19-CAR T cells (CART19) with anti-HER2 or anti-EGFR bispecific antibodies (BiAb) will target HER2 + /EGFR + CD19 - targets and signal the intracellular domain of CAR without engaging antigen-specific CD19 ScFv of CAR T cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research